SPOTLIGHT -
Hydroxychloroquine for COVID-19: A Lesson in Study Quality
Read More
COVID-19 Preprints: Reader, Beware
In his June Editor-in-Chief letter, Dr. Jason Gallagher explores the influence of preprints amid the COVID-19 pandemic.
COVID-19: How Temple University Hospital Is Addressing the Pandemic
The health system’s response could be used as a teaching model for addressing future infectious disease threats.
COVID-19 Is Moving Quickly, But Let's Take Notes
COVID-19 does not present our first pandemic, nor will it be our last. What should we take note of?
Oseltamivir on the Move, but Where Should It Go?
Just as influenza season started ramping up in the Northern Hemisphere, news hit the wire that Sanofi had secured over-the-counter rights for oseltamivir (Tamiflu).
The Year Ends With a Big Step in PrEP and PEP
Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.
Antibiotic Resistance: Patients Don't Get It, and We Need to Help
In the October Editor-in-Chief letter, Dr. Jason Gallagher writes about the role clinicians play in helping patients understand antibiotic resistance.
Improving Outpatient Antimicrobial Stewardship: Taking the Next Step
In the August Editor-in-Chief's Letter, Dr. Jason Gallagher discusses how we can improve outpatient antimicrobial stewardship.
Achaogen—Canary in the Coal Mine or Developer of an Unwanted Product?
The June Editor-in-Chief letter by Dr. Jason Gallagher tackles the story of Achaogen and what its bankruptcy means for antibiotic development.
HIV Infection in 2019: A Cure Is Not the Real News
Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection.
New Year, New Contagion®: Section Editor Lineup Brings Expertise, Insight for 2019
Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, kicks off his second year as editor-in-chief by welcoming 6 industry experts on as section editors.
Lessons From a Year Full of Infectious Disease Firsts
Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on 2018 and his first full year as Contagion®'s editor-in-chief.